Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Newamsterdam Pharma Co. N.V.
Headquarters: Naarden, Netherlands
Website: https://www.newamsterdampha...
Year Founded: 2019
Status: Public
Industry Sector: HealthTechnology
CEO: Michael H. Davidson, MD
Number Of Employees: 68
Enterprise Value: $1,591,260,322
PE Ratio: -6.08
Exchange/Ticker 1: NASDAQ:NAMS
Exchange/Ticker 2: N/A
Latest Market Cap: $1,736,222,720
BioCentury | Dec 14, 2024
Finance
Data spells money for a quintet of biotechs
NewAmsterdam’s CETP readout leads to week’s largest follow-on
BioCentury | Dec 11, 2024
Product Development
ROR1 shines as the next promising ADC target
Also in BioCentury’s Clinical Report: ASH readouts from Cardiff Oncology, Arcellx and GSK; plus data from NewAmsterdam, AbbVie and more
BioCentury | Jul 31, 2024
Product Development
Clinical Report: BioNTech claims mRNA cancer vaccine success
Plus data from NewAmsterdam, Pfizer, Calliditas, Ventyx and Viking
BioCentury | Apr 3, 2024
Management Tracks
Takeda vet Tanigaki named CEO of Aculys
Plus: Lonza names Wolfgang Wienand CEO, and updates from Verily, GSK, NewAmsterdam, Voyager, Adaptive, Ratio, Adlai Nortye and I-Mab
BioCentury | Feb 17, 2024
Finance
Public equity report: Five follow-ons total $875M+, PIPEs keep flowing
Plus: LianBio begins winding down, promises dividend; BioXcel pulls offering
BioCentury | Jan 10, 2024
Management Tracks
Mark Alles at the helm at Torl
Plus: new CSO at Nutcracker, and updates from
BioCentury | Oct 24, 2023
Management Tracks
Viatris’ Malik to retire in April
Plus: New CFO for NewAmsterdam and more from Persephone, Eledon and Attgeno
BioCentury | Sep 13, 2023
Management Tracks
CEO Nick Leschly shifting to chair as 2seventy bio restructures
Plus: CFO Galá promoted at Jazz, and updates from Geron, Mirum, ReNAgade,
BioCentury | Aug 18, 2023
Management Tracks
CSL names first chief sustainability officer
Plus: Jones hired as CCO at NewAmsterdam, and updates from Foresight, Kronos, Antheia and more
BioCentury | Dec 21, 2022
Data Byte
Pace of biotech-SPAC mergers remains steady in 2H22
SPACs continue to be a viable IPO alternative, with at least 10 biotechs expecting to start trading in 1H23
Items per page:
1 - 10 of 12